4.0 Article

Presynaptic dopaminergic dysfunction in schizophrenia -: A positron emission tomographic [18F]fluorodopa study

Journal

ARCHIVES OF GENERAL PSYCHIATRY
Volume 61, Issue 2, Pages 134-142

Publisher

AMER MEDICAL ASSOC
DOI: 10.1001/archpsyc.61.2.134

Keywords

-

Categories

Ask authors/readers for more resources

Context: The dopamine overactivity hypothesis of schizophrenia remains one of the most influential theories of the pathophysiology of the illness. Radiotracer brain imaging studies are now directly testing aspects of the overactivity hypothesis. Objective: To assess presynaptic dopaminergic function in a large cohort of patients with schizophrenia by means of [F-18]fluorodopa uptake and a high-sensitivity 3-dimensional positron emission tomograph. We predicted elevations in striatal [F-18]fluorodopa uptake and reductions in prefrontal cortical [F-18]fluorodopa uptake in patients with schizophrenia. Design: Case-control study. Setting: Research institute investigation recruiting hospital outpatients. Patients: Sixteen male medicated hospital outpatients with a DSM-IV diagnosis of schizophrenia (mean age, 38 years) and 12 age-matched male volunteers free of psychiatric and neurologic illness. Intervention: [F-18]fluorodopa positron emission tomographic scanning. Main Outcome Measure: [F-18]fluorodopa uptake constant K-i measured with statistical parametric mapping and region-of-interest analyses. Results: Statistical parametric mapping (P<.05 corrected) and region-of-interest analyses (P<.01) showed increased [F-18] fluorodopa uptake, confined primarily to the ventral striatum in patients with schizophrenia. No reductions in prefrontal cortical [F-18]fluorodopa uptake Ki were seen in the statistical parametric mapping and region-of-interest analyses, although dorsal anterior cingulate [F-18] fluorodopa K-i correlated with performance on the Stroop Color-Word Test in both groups. Conclusions: As in studies in unmedicated patients, presynaptic striatal dopamine dysfunction is present in medicated schizophrenic patients, adding further in vivo support for dopamine overactivity in the illness.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available